Home > Search Results

Results: 1 to 20 of 48

This review is not appropriate for update since radiotherapy is now routinely combined with cisplatin and there have been no further studies using hydroxyurea.

The orally‐administered cytotoxic, hydroxyurea, may be given alongside radiotherapy for treating cervix cancer. Eight trials comparing concomitant hydroxyurea and radiotherapy with radiotherapy alone were assessed. They were not of sufficient quality to be able to pool the data. Although several trials reported an improvement in survival for patients receiving hydroxyurea, this conclusion was unreliable owing to methodological problems associated with trials including small sample size, a large number of patients excluded from analysis and questionable methods of analysis such as exclusion of treatment related deaths.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2015

Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias

We wanted to find out if giving hydroxyurea to people with non‐transfusion dependent beta thalassaemia would reduce the need for blood transfusion.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease

SCD is an inherited genetic disorder that creates problems with haemoglobin (the substance in red blood cells that carries oxygen around the body). The disease can be inherited in different ways; people can inherit two sickle genes (HbSS genotype) or they can inherit the sickle gene from one parent and a different haemoglobin gene (such as haemoglobin C (HbSC genotype) or a beta thalassaemia gene (HbSβ+ or HbSβºthal genotype)) from the second parent.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

Drug treatment for spinal muscular atrophy types II and III

Spinal muscular atrophy (SMA) is a neuromuscular disorder that results in progressive muscle weakness with onset in childhood and adolescence. There are three main types of SMA. Drug treatment for SMA type I is discussed in a separate Cochrane review. This review is of drug treatment for SMA types II and III. Both of these reviews were first published in 2009 and are now updated. The age of onset of SMA type II is between six and 18 months. Children with SMA type II will never be able to walk without support; they survive beyond two years and may live into adolescence or longer. The age of onset of SMA III, also known as Kugelberg‐Welander disease, is after 18 months. Children with SMA type III develop the ability to walk at some time and their life expectancy is normal. From six randomised controlled trials, there is no evidence for a significant effect on the disease course when patients with SMA types II and III are treated with creatine (55 participants), phenylbutyrate (107 participants), gabapentin (84 participants), thyrotropin releasing hormone (9 participants), hydroxyurea (57 participants) or combination therapy with valproate and acetyl‐L‐carnitine (61 participants). The risk of bias of the included trials was systematically analysed and none of the studies were completely free of bias. Thus, there is still no known efficacious drug treatment for SMA types II and III.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

The effect of long‐term red blood cell transfusions on chronic chest complications of sickle cell disease

We reviewed the evidence to see if regular long‐term red blood cell transfusions helped to reduce the occurrence or progression of chronic chest complications compared to hydroxycarbamide (hydroxyurea), any other treatment or standard care in people with sickle cell disease.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Combinations of anti‐cancer drugs to treat high‐risk cancers arising from the placenta, known as high‐risk gestational trophoblastic neoplasia (GTN)

GTN is a cancer that most often arises after a molar pregnancy but can arise after any type of pregnancy. Molar pregnancies occur due to abnormal growth of placental tissue that is usually benign and treated by evacuation of the womb (D&C). However, in less than 10% of molar pregnancies in the UK, the growth remains after D&C and transforms into a cancer (GTN) that needs treatment with anti‐cancer drugs (chemotherapy). GTN can be low‐risk or high‐risk. Anti‐cancer drugs are very effective, especially in low‐risk GTN, which is usually cured with single‐drug treatment. However, high‐risk GTN needs to be treated with combinations of anti‐cancer drugs for the best effect. These drugs can produce toxic side effects that are more likely to occur when used in combination with each other. The most commonly administered drug combination is abbreviated as EMA/CO, which stands for Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Oncovin® (vincristine), but several other combinations are also in use.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Long‐term blood transfusions to prevent a stroke in people with sickle cell disease

We wanted to determine if long‐term blood transfusions given to people with sickle cell disease who are at a higher risk of stroke (primary prevention) or have had a previous stroke (secondary prevention) decreases their risk of a subsequent stroke without causing severe side effects. We compared long‐term blood transfusions to standard treatment or other ways of preventing a stroke. This is an update of a previously published Cochrane Review.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012

Hydroxyurea (HU) is being used for patients with transfusion-dependent β-thalassemia major (β-TM) as well as non transfusion-dependent β-TM. As controversy exists regarding efficacy and safety of HU, we searched the published literature on efficacy, effectiveness and toxicity of HU in patients with β-TM. The research sources we used were: Medline, SID, PubMed, Scopus, Request, Web of Knowledge, Springer, Ovid, Cochrane searched up to October 2012. Using search terms sensitive to studies of clinical trials combined with searches on terms related to thalassemia and HU. We selected studies on randomized trials, quasi experimental trials (before and after design), case reports (with 1-5 cases), side effect studies in patients with β-TM, studies related to the mechanism of action and toxicity when used in patients with other hemoglobinopathies. We researched studies in English and Persian. Eligible articles were reviewed by two independent reviewers. Patient's characteristics, duration of trial, outcome and side effects were extracted. The main outcomes were synthesized under a random-effects model. Heterogeneity was assessed using the Q statistic, Tau(2) and I(2). Subgroup analyses were performed and the statistics data (STATA) software used. More than 500 articles were reviewed. No randomized clinical trial was found. Seventeen trials with before and after designs were found, 16 case reports (1-5 cases), 19 articles for mechanism of action and 16 studies for side effects were published from 1969 to October 2012. Hemoglobin levels after treatment showed modest but significant increase in non transfusion-dependent β-TM (p < 0.0001) and in transfusion-dependent β-TM (p < 0.0001).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Hydroxyurea for the treatment of sickle cell disease

The review investigated the evidence surrounding the efficacy, effectiveness and toxicity of hydroxyurea in the treatment of sickle cell disease. The authors found that hydroxyurea was efficacious, but that there was insufficient evidence regarding effectiveness and toxicity. The review was well conducted, but it was based on only two randomised studies and generally moderate to low quality observational studies, so the results may be unreliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

The management of malignant thrombocytosis in Philadelphia chromosome-negative myeloproliferative disease: guideline recommendations

Bibliographic details: Matthews J H, Smith C A, Herst J, Lee D, Imrie K, Hematology Disease Site Group.  The management of malignant thrombocytosis in Philadelphia chromosome-negative myeloproliferative disease: guideline recommendations. This paper is produced by Cancer Care Ontario Practice Guidelines Initiative. The series is published on the Internet and regularly updated. To ensure that you are viewing the most up to date version, go to the Cancer Care Ontario website at: https://www.cancercare.on.ca/toolbox/qualityguidelines/ Available from: http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34319

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation

BACKGROUND: Sickle cell disease (SCD) is a recessive genetic blood disorder, caused by a mutation in the β-globin gene. For children with SCD, the risk of stroke is estimated to be up to 250 times higher than in the general childhood population. Transcranial Doppler (TCD) ultrasonography is a non-invasive technique which measures local blood velocity in the proximal portions of large intracranial arteries. Screening with TCD ultrasonography identifies individuals with high cerebral blood velocity; these children are at the highest risk of stroke. A number of primary stroke prevention strategies are currently used in clinical practice in the UK including blood transfusion, treatment with hydroxycarbamide and bone marrow transplantation (BMT). No reviews have yet assessed the clinical effectiveness and cost effectiveness of primary stroke prevention strategies in children with SCD identified to be at high risk of stroke using TCD ultrasonography.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

The Clinical Effectiveness and Cost-Effectiveness of Primary Stroke Prevention in Children with Sickle Cell Disease: A Systematic Review and Economic Evaluation

Sickle cell disease (SCD) is a recessive genetic blood disorder, caused by a mutation in the β-globin gene. For children with SCD, the risk of stroke is estimated to be up to 250 times higher than in the general childhood population. Transcranial Doppler (TCD) ultrasonography is a non-invasive technique which measures local blood velocity in the proximal portions of large intracranial arteries. Screening with TCD ultrasonography identifies individuals with high cerebral blood velocity; these children are at the highest risk of stroke. A number of primary stroke prevention strategies are currently used in clinical practice in the UK including blood transfusion, treatment with hydroxycarbamide and bone marrow transplantation (BMT). No reviews have yet assessed the clinical effectiveness and cost effectiveness of primary stroke prevention strategies in children with SCD identified to be at high risk of stroke using TCD ultrasonography.

Health Technology Assessment - NIHR Journals Library.

Version: November 2012
Show search results within this document

Magnesium for treating sickle cell disease

We reviewed the evidence of the effect of intravenous (given into a vein) magnesium and oral (taken by mouth) magnesium on the frequency of painful crises (sickle cell crises with severe pain due to blockages of the blood supply to bones, joints, lungs, liver, spleen, kidney, eye or central nervous system), length of hospital stay and quality of life in people with different types of sickle cell disease.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

Interventions to prevent silent strokes in people with sickle cell disease

We wanted to determine if there were any safe and effective interventions that prevent silent strokes (also known as silent cerebral infarcts) in people with sickle cell disease (SCD).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation

Chronic myeloid leukaemia (CML) is a form of cancer affecting the blood, characterised by excessive proliferation of white blood cells in the bone marrow and circulating blood. In the UK, an estimated 560 new cases of CML are diagnosed each year.

Health Technology Assessment - NIHR Journals Library.

Version: April 2012
Show search results within this document

Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation

The present report was commissioned as a supplement to an existing technology assessment report produced by the Peninsula Technology Assessment Group (PenTAG), which evaluated the clinical effectiveness and cost-effectiveness of dasatinib and nilotinib in patients who are either resistant or intolerant to standard-dose imatinib.

Health Technology Assessment - NIHR Journals Library.

Version: May 2012
Show search results within this document

Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update [Internet]

This guideline is a partial update of NICE Guideline No 5: Chronic Heart Failure - national clinical guideline for diagnosis and management in primary and secondary care (2003). The aim of the 2003 guideline was to offer best practice advice on the care of adult patients (aged 18 years or older) who have symptoms or a diagnosis of chronic heart failure. It defined the most effective combination of symptoms, signs and investigations required to establish a diagnosis of heart failure, and those which would influence therapy or provide important prognostic information. It also gave guidance on the treatment, monitoring and support of patients with heart failure.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: August 2010
Show search results within this document

Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis

Chronic myeloid leukaemia (CML) is a rare blood cancer with an incidence of 1.0 per 100,000 for men and 0.8 per 100,000 for women. In CML, excessive numbers of leukaemic white blood cells are produced that suppress the production of normal white blood cells. In 95% of cases a specific chromosomal abnormality, the Philadelphia chromosome, is present. This is a reciprocal translocation between part of the long arm of chromosome 22 and chromosome 9. The consequent molecular abnormality is a fusion protein, BCR-ABL, which is a tyrosine kinase. There are three identifiable phases of chronic myeloid leukaemia: chronic, accelerated and blast phase, with blast phase being fatal within 3-6 months.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2004

Interventions to prevent or reduce kidney complications in people with sickle cell disease

We wanted to determine if there were any safe and effective interventions that prevent or reduce kidney complications in people with sickle cell disease (SCD).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 21, 2015

Systematic Reviews in PubMed

See all (146)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...